- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in Sinopharm
Sri Lanka puts Chinese Covid-19 vaccine on hold
Sri Lanka puts Chinese Covid-19 vaccine on hold
Read MoreWide-scale irregularities found in administration of Chinese Sinopharm vaccine in Pak's Sindh
Wide-scale irregularities found in administration of Chinese Sinopharm vaccine in Pak's Sindh
Read MoreIraq approves Sinopharm, AstraZeneca COVID-19 vaccines for emergency use
Iraq approves Sinopharm, AstraZeneca COVID-19 vaccines for emergency use
Read MorePakistan approves Chinese Sinopharm COVID -19 vaccine for emergency use
Pakistan approves Chinese Sinopharm COVID -19 vaccine for emergency use
Read MoreAmid global criticism, China approves Sinopharm vaccine for general use
Amid global criticism, China approves Sinopharm vaccine for general use
Read MoreEgypt's COVID-19 daily cases exceed 1,000, 128,993 in total
Egypt's COVID-19 daily cases exceed 1,000, 128,993 in total
Read MoreMorocco to buy 65 million doses of COVID-19 vaccine
Morocco to buy 65 million doses of COVID-19 vaccine
Read More
China's Sinopharm Offers Experimental COVID-19 Vaccines To Students
China launched a vaccine emergency use programme in July, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group and U.S.-listed Sinovac Biotech.
Read More
China's Sinopharm Says Coronavirus Vaccine Could Be Ready By Year-End - State Media
Sinopharm's experimental shot has entered a Phase III trial involving around 15,000 participants and two vaccine strains in the United Arab Emirates.
Read More